249 related articles for article (PubMed ID: 33911178)
1. Identification of therapeutic targets of the hijacked super-enhancer complex in EVI1-rearranged leukemia.
Kiehlmeier S; Rafiee MR; Bakr A; Mika J; Kruse S; Müller J; Schweiggert S; Herrmann C; Sigismondo G; Schmezer P; Krijgsveld J; Gröschel S
Leukemia; 2021 Nov; 35(11):3127-3138. PubMed ID: 33911178
[TBL] [Abstract][Full Text] [Related]
2. Two effects of GATA2 enhancer repositioning by 3q chromosomal rearrangements.
Suzuki M; Katayama S; Yamamoto M
IUBMB Life; 2020 Jan; 72(1):159-169. PubMed ID: 31820561
[TBL] [Abstract][Full Text] [Related]
3. GATA2 haploinsufficiency accelerates EVI1-driven leukemogenesis.
Katayama S; Suzuki M; Yamaoka A; Keleku-Lukwete N; Katsuoka F; Otsuki A; Kure S; Engel JD; Yamamoto M
Blood; 2017 Aug; 130(7):908-919. PubMed ID: 28630119
[TBL] [Abstract][Full Text] [Related]
4. Atypical 3q26/MECOM rearrangements genocopy inv(3)/t(3;3) in acute myeloid leukemia.
Ottema S; Mulet-Lazaro R; Beverloo HB; Erpelinck C; van Herk S; van der Helm R; Havermans M; Grob T; Valk PJM; Bindels E; Haferlach T; Haferlach C; Smeenk L; Delwel R
Blood; 2020 Jul; 136(2):224-234. PubMed ID: 32219447
[TBL] [Abstract][Full Text] [Related]
5. A remote GATA2 hematopoietic enhancer drives leukemogenesis in inv(3)(q21;q26) by activating EVI1 expression.
Yamazaki H; Suzuki M; Otsuki A; Shimizu R; Bresnick EH; Engel JD; Yamamoto M
Cancer Cell; 2014 Apr; 25(4):415-27. PubMed ID: 24703906
[TBL] [Abstract][Full Text] [Related]
6. [Chromosomal rearrangements between 3q21 and 3q26 induce leukemogenesis by misdirecting both EVI1 and GATA2 genes].
Suzuki M
Rinsho Ketsueki; 2017; 58(7):806-812. PubMed ID: 28781278
[TBL] [Abstract][Full Text] [Related]
7. The leukemic oncogene EVI1 hijacks a MYC super-enhancer by CTCF-facilitated loops.
Ottema S; Mulet-Lazaro R; Erpelinck-Verschueren C; van Herk S; Havermans M; Arricibita Varea A; Vermeulen M; Beverloo HB; Gröschel S; Haferlach T; Haferlach C; J Wouters B; Bindels E; Smeenk L; Delwel R
Nat Commun; 2021 Sep; 12(1):5679. PubMed ID: 34584081
[TBL] [Abstract][Full Text] [Related]
8. A single oncogenic enhancer rearrangement causes concomitant EVI1 and GATA2 deregulation in leukemia.
Gröschel S; Sanders MA; Hoogenboezem R; de Wit E; Bouwman BAM; Erpelinck C; van der Velden VHJ; Havermans M; Avellino R; van Lom K; Rombouts EJ; van Duin M; Döhner K; Beverloo HB; Bradner JE; Döhner H; Löwenberg B; Valk PJM; Bindels EMJ; de Laat W; Delwel R
Cell; 2014 Apr; 157(2):369-381. PubMed ID: 24703711
[TBL] [Abstract][Full Text] [Related]
9. EVI1 and GATA2 misexpression induced by inv(3)(q21q26) contribute to megakaryocyte-lineage skewing and leukemogenesis.
Yamaoka A; Suzuki M; Katayama S; Orihara D; Engel JD; Yamamoto M
Blood Adv; 2020 Apr; 4(8):1722-1736. PubMed ID: 32330245
[TBL] [Abstract][Full Text] [Related]
10. Functional characterization of the promoter region of the human EVI1 gene in acute myeloid leukemia: RUNX1 and ELK1 directly regulate its transcription.
Maicas M; Vázquez I; Vicente C; García-Sánchez MA; Marcotegui N; Urquiza L; Calasanz MJ; Odero MD
Oncogene; 2013 Apr; 32(16):2069-78. PubMed ID: 22689058
[TBL] [Abstract][Full Text] [Related]
11. The +37 kb Cebpa Enhancer Is Critical for Cebpa Myeloid Gene Expression and Contains Functional Sites that Bind SCL, GATA2, C/EBPα, PU.1, and Additional Ets Factors.
Cooper S; Guo H; Friedman AD
PLoS One; 2015; 10(5):e0126385. PubMed ID: 25938608
[TBL] [Abstract][Full Text] [Related]
12. Selective Requirement of MYB for Oncogenic Hyperactivation of a Translocated Enhancer in Leukemia.
Smeenk L; Ottema S; Mulet-Lazaro R; Ebert A; Havermans M; Varea AA; Fellner M; Pastoors D; van Herk S; Erpelinck-Verschueren C; Grob T; Hoogenboezem RM; Kavelaars FG; Matson DR; Bresnick EH; Bindels EM; Kentsis A; Zuber J; Delwel R
Cancer Discov; 2021 Nov; 11(11):2868-2883. PubMed ID: 33980539
[TBL] [Abstract][Full Text] [Related]
13. RUNX1-ETO and RUNX1-EVI1 Differentially Reprogram the Chromatin Landscape in t(8;21) and t(3;21) AML.
Loke J; Assi SA; Imperato MR; Ptasinska A; Cauchy P; Grabovska Y; Soria NM; Raghavan M; Delwel HR; Cockerill PN; Heidenreich O; Bonifer C
Cell Rep; 2017 May; 19(8):1654-1668. PubMed ID: 28538183
[TBL] [Abstract][Full Text] [Related]
14. RUNX1-ETO Depletion in t(8;21) AML Leads to C/EBPα- and AP-1-Mediated Alterations in Enhancer-Promoter Interaction.
Ptasinska A; Pickin A; Assi SA; Chin PS; Ames L; Avellino R; Gröschel S; Delwel R; Cockerill PN; Osborne CS; Bonifer C
Cell Rep; 2019 Sep; 28(12):3022-3031.e7. PubMed ID: 31533028
[TBL] [Abstract][Full Text] [Related]
15. Preclinical efficacy of targeting epigenetic mechanisms in AML with 3q26 lesions and EVI1 overexpression.
Birdwell CE; Fiskus W; Kadia TM; Mill CP; Sasaki K; Daver N; DiNardo CD; Pemmaraju N; Borthakur G; Davis JA; Das K; Sharma S; Horrigan S; Ruan X; Su X; Khoury JD; Kantarjian H; Bhalla KN
Leukemia; 2024 Mar; 38(3):545-556. PubMed ID: 38086946
[TBL] [Abstract][Full Text] [Related]
16. Enhancer recruitment of transcription repressors RUNX1 and TLE3 by mis-expressed FOXC1 blocks differentiation in acute myeloid leukemia.
Simeoni F; Romero-Camarero I; Camera F; Amaral FMR; Sinclair OJ; Papachristou EK; Spencer GJ; Lie-A-Ling M; Lacaud G; Wiseman DH; Carroll JS; Somervaille TCP
Cell Rep; 2021 Sep; 36(12):109725. PubMed ID: 34551306
[TBL] [Abstract][Full Text] [Related]
17. Helicase-like transcription factor is a RUNX1 target whose downregulation promotes genomic instability and correlates with complex cytogenetic features in acute myeloid leukemia.
Cheng CK; Chan NP; Wan TS; Lam LY; Cheung CH; Wong TH; Ip RK; Wong RS; Ng MH
Haematologica; 2016 Apr; 101(4):448-57. PubMed ID: 26802049
[TBL] [Abstract][Full Text] [Related]
18. Orthogonal proteogenomic analysis identifies the druggable PA2G4-MYC axis in 3q26 AML.
Marchesini M; Gherli A; Simoncini E; Tor LMD; Montanaro A; Thongon N; Vento F; Liverani C; Cerretani E; D'Antuono A; Pagliaro L; Zamponi R; Spadazzi C; Follini E; Cambò B; Giaimo M; Falco A; Sammarelli G; Todaro G; Bonomini S; Adami V; Piazza S; Corbo C; Lorusso B; Mezzasoma F; Lagrasta CAM; Martelli MP; La Starza R; Cuneo A; Aversa F; Mecucci C; Quaini F; Colla S; Roti G
Nat Commun; 2024 Jun; 15(1):4739. PubMed ID: 38834613
[TBL] [Abstract][Full Text] [Related]
19. The creatine kinase pathway is a metabolic vulnerability in EVI1-positive acute myeloid leukemia.
Fenouille N; Bassil CF; Ben-Sahra I; Benajiba L; Alexe G; Ramos A; Pikman Y; Conway AS; Burgess MR; Li Q; Luciano F; Auberger P; Galinsky I; DeAngelo DJ; Stone RM; Zhang Y; Perkins AS; Shannon K; Hemann MT; Puissant A; Stegmaier K
Nat Med; 2017 Mar; 23(3):301-313. PubMed ID: 28191887
[TBL] [Abstract][Full Text] [Related]
20. All-trans retinoic acid enhances, and a pan-RAR antagonist counteracts, the stem cell promoting activity of EVI1 in acute myeloid leukemia.
Nguyen CH; Bauer K; Hackl H; Schlerka A; Koller E; Hladik A; Stoiber D; Zuber J; Staber PB; Hoelbl-Kovacic A; Purton LE; Grebien F; Wieser R
Cell Death Dis; 2019 Dec; 10(12):944. PubMed ID: 31822659
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
